Indira Brar

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Samia Arshad, Paul E. Kilgore, Zohra Chaudhry et al. · International Journal of Infectious Diseases · 2020 · 564 citations · Full text

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 362 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2015 · 304 citations

Hiv/aids Counselling, Treatment And Prevention, Pharmacology +11

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

Paul E. Sax, Andrew Zolopa, Indira Brar et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 206 citations

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Jean‐Michel Molina, Douglas Ward, Indira Brar et al. · The Lancet HIV · 2018 · 192 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +10